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Figure 1. Decrease in GoTN Times from Pre to Post-
Intervention while DTN Times Remained the Same. 
• In 2010, the AHA/ASA’s Target Stroke best practice recommendations to reduce door to needle times
(DTN) included early pre-mix of intravenous alteplase.
• Early premixing of alteplase has led to unused vials. The price for replacement vials range from $6,400 to
$8,400 per 100mg vial. However, hospitals have largely recouped the cost of wasted alteplase by
returning them to the drug manufacture for free replacement vials.
• Our Primary Stroke Center (PSC) had a high return rate prompting our team to implement interventions
aimed at ethical stewardship of resources without compromising clinical care.
• Objective: Evaluate whether specific interventions reduced clinical expenses without affecting timeliness
of clinical care at our PSC
• The following intervention was implemented between July–Sept 2015:
o Establishing a dedicated pharmacist in the ED to mix alteplase at bedside Friday–Tuesday, 12:30–21:00,
in addition to existing satellite pharmacy available all other times
o Implementing single call number from neurology to pharmacist to initiate treatment
o Educating neurologist on current alteplase waste and cost per vial
• Clinical data were from the American Stroke Association’s Get with the Guidelines database; alteplase vial
usage was from the pharmacy’s internal quality tracking database
• Data from Acute Ischemic Stroke (AIS) patients presenting at our PSC emergency room within 4.5 hours of
Last Known Well (LKW) and treated with IV-alteplase between Jan–June 2015 & Sept–Nov 2016 were
included
• Exclusions: inpatient strokes or those with diagnoses unrelated to stroke; alteplase mixes during the
implementation phase (July–August, 2015)
• Pre-intervention cases (Jan–June 2015) were compared to post-intervention cases (Sept 2015–Nov 2016)
• Primary outcomes:
o Change in % returned vials (total vials returned/total vials mixed) between pre- and post-intervention time
periods
o Expected number of post-intervention vials that would have been returned using pre-intervention percent
returned was calculated to assess costs
o Costs were derived using the number of expected returned vials vs actual number of returned vials (cost =
# of vials * cost/vial). Costs were estimated as a range between $6400–$8400 per returned 100mg vial.
Cost Savings = ‘expected’ minus ‘actual’ returns for the post-intervention time period
• Secondary outcomes: median DTN and median pharmacy go-ahead call time to needle time (GoTN); Mann-
Whitney test was used to compare DTN and GoTN between pre and post- intervention time periods
• A sub-analysis of patients treated during the post-intervention time period was used to determine whether
GoTN or DTN differed depending on location of alteplase mixing (satellite pharmacy vs ED bedside); Mann
Whitney tests were used to determine differences.
• Data from 126 alteplase administered AIS patients were included
• Pre-intervention alteplase returns was 39.5% (15/38) versus 11.3%
(10/88) post-intervention (Table 1)
• Post-intervention, the observed number of returned vials was lower
than expected (10 vs 35) (Table 1)
• Pre-intervention expected cost of returned vials ranged from
$96,000–$126,000, post-intervention expected cost was $76,800–
$100,800, equaling cost-savings of $166,400–$218,400 (Table 1)
• Percentage of vials returned decreased substantially following the intervention and
resulted in extensive cost savings
• PSCs can reduce overall waste of alteplase and decrease costs without negatively
effecting clinical care
• Stroke programs need to stay aware of both the increasing costs of alteplase and
changes in replacement policies, including the November 2016 change from 6 months to
30 days with a physician or pharmacy director signature required for reimbursement
• Continued research is needed to assess the impact of other interventions aimed at
reducing DTN times in the ED and its effect on alteplase waste
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Table 1. Cost Savings in the Post-Intervention Time Period.
• DTN was not significantly different post- vs pre-intervention (median
[IQR]=51.0 min [36.8,68.0] vs 52.0 min [40.0,68.0]; p=0.966) (Figure 1).
• GoTN was significantly faster post- vs pre-intervention (median
[IQR]=10.0 min. [8.0,14.8] vs 16.0 min. [11.5,19.5]; p=.011) (Figure 1).
• Sub-analysis among post-intervention cases found that DTN and GoTN
were not significantly different when pharmacy mixed alteplase in the ED
compared to the satellite pharmacy (median DTN [IQR]=45.0 min [35.0,
68.0] vs. 53.0 min [42.0, 68.0]; p=0.701) & median GoTN [IQR]=8.00 min
[6.0, 13.0] vs. 11.00 min [9.0,14.75], respectively.
a Calculation based 
on 88 post-
intervention mixes. 
b Actual number of 
mixes returned in 
post-intervention 
time period.
c Minimum Cost = 
number of mixes 
returned*minimum 
cost per mix, 
$6,400/vial
d Maximum Cost = 
number of mixes 
returned*maximum 
cost per mix, 
$8,400/vial
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